Glucosamine and chondroitin, either alone or in combination, have no clinically relevant effect on joint pain in osteoarthritis, according to a BMJ meta-analysis.

The authors analyzed results from 10 randomized trials encompassing some 3800 patients allocated to glucosamine, chondroitin, both, or placebo. Reductions in pain scores in some trials, although occasionally attaining statistical significance at certain time points, did not reach clinical relevance.

The authors conclude: “We are confident that neither of the preparations is dangerous. Therefore, we see no harm in having patients continue these preparations as long as they perceive a benefit and cover the costs of treatment themselves.”

souece:BMJ